



P H A R M A U K L T D

Introduction

BIAL Pharma UK Ltd was established in the UK in May 2016. The company is a wholly owned subsidiary of Bial Portela & C^a., S.A; a Portugal Headquartered Pharmaceutical company.

This disclosure submission relates solely to the UK operation of BIAL Pharma UK Ltd. EFPIA states that the collaboration between the pharmaceutical industry and Healthcare Professionals / organisations benefits patients. Collaborative working has been a driver for advancements in patient care and helps the progression of innovative medicine.

HCPs and HCOs are fairly compensated for the legitimate expertise and services that they provide to the industry. We acknowledge that such transactions should be transparent.

This note describes the methods used by Bial Pharma UK Ltd to meet the obligations for disclosing Transfers of Value (ToV) made to HCPs and HCOs under the EFPIA HCP/HCO Disclosure Code and as reflected in the IPHA Code of Practice

Definitions

Healthcare Professionals

Healthcare Professional (HCP) HCPs include members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their activities may administer, prescribe, purchase, recommend or supply a medicine.

Healthcare Organisations

HCO means either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more HCPs or other relevant decision makers provide services.

Other Relevant Decision Maker

(ORDM) ORDMs particularly include those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not HCPs.

- Kind of ToVs (donations and grants – contribution to costs of events – fees for services and consultancy – R&D¹ – others)

Disclosure's scope

- Products concerned - Prescribed Only Medicines
- Company concerned – Bial Pharma UK Ltd
- ToVs date- 01/01/2025 – 31/12/2025
- Direct ToVs – All disclosures reported are Direct ToV
- Cross-border activities – No cross-border activities in this disclosure period
- R&D – No R&D in this disclosure period
- Voluntary disclosure - N/A in this disclosure

Specific considerations

- Self-incorporated HCP – N/A in this disclosure report
- Multi-year agreements - N/A in this disclosure report
- Country specificities - N/A in this disclosure report
-

Data protection legal basis

- Consent collection
- Those that did not consent will be shown in aggregate

Form of Disclosure

- Date of publication 18.05.2026
- Disclosure platform IPHA ToV
- Disclosure language - English

Disclosure financial data

- Currency - Local
- VAT Excluded
- Calculation rules – Currency exchange at time of payment

Additional information

¹ Cf. EFPIA's R&D best practice guidance: <https://efpia.box.com/s/nms7cod07bbkwwjenr3kcyerdk17k4xw>